Re-purposing is often touted as a good idea (we see a lot of pitches across many disease areas) BUT it less of a good idea than it first appears - because biology risk is usually the biggest risk in any project and re-purposing doesn’t solve that...
If you have good target validation, finding a good tool to modulate it (be it small molecule, biologic or nucleus acid) is usually relatively cheap and easy compared to the act of obtaining clinical proof-of-concept (proving the biology)
The only time re-purposing should come into its own is when sped is absolutely key (as with #COVID-19) - but it’s in precisely in these situations that our understanding of the biology us weakest... as the very low hit-rate from re-purposing efforts has amply proven
